8:45am ET
Investing
Stock Splits Matter: Here’s What’s Coming Up Soon
Here is a look at why companies split their stocks and why it matters. Plus, upcoming stock splits to watch from a Coca-Cola bottler, Southern Copper, and more.
Companies
/Healthcare
Seres Therapeutics Inc
$4.95
â–² $0.19 (+3.99%) today
Markets closed · 9:13pm ET
Today · % change
Fundamentals
Market Cap
$50.2M
Revenue (TTM)
$1.9M
EPS (TTM)
$-2.59
52-Week Range
$4 – $30
Street Target
$17.00
About Seres Therapeutics
Seres Therapeutics Inc is at the forefront of developing microbiome therapeutics, focusing on restoring health by modulating the microbiome. Their leading product, SER-109, aims to treat recurrent Clostridioides difficile infection and has completed Phase III clinical trials. The company's pipeline also includes treatments for gastrointestinal infections and ulcerative colitis, among others. Through strategic partnerships, Seres Therapeutics is advancing research in microbiome technology for various diseases, including cancer. Founded in 2010 and based in Cambridge, Massachusetts, the company is pioneering in leveraging the microbiome for therapeutic purposes.
MCRB Coverage
8:37am ET
Investing
15 Companies That Had Their IPO in 2015: Best and Worst Performers
2015 was one of the worst years for IPOs in the past decade. Only 2016 and 2022 were worse. But there were some big winners.
8:35am ET
Investing
Cathie Wood’s ARK Invest Sells Over 840,000 Shares of Seres Therapeutics
One of Cathie Wood's ARK Invest exchange-traded funds sold over 840,000 shares of Seres Therapeutics on August 30.
8:42am ET
Investing
Friday’s Top Analyst Upgrades and Downgrades: American Airlines, Boston Beer, CarMax, Danaher, Domino’s, Monster, Starbucks and More
Friday's top analyst upgrades and downgrades included American Airlines, Boston Beer, CarMax, Danaher, Domino’s Pizza, D.R. Horton, Monster Beverage and Starbucks.
9:12am ET
Investing
Top Analyst Upgrades and Downgrades: Bed Bath & Beyond, Booking, Carvana, EA, EOG, Honeywell, ICE, Livongo, Nucor, Seres, Sunrun and More
Tuesday's top analyst upgrades and downgrades included Bed Bath & Beyond, Booking, Carvana, Electronic Arts, EOG Resources, Honeywell, Intercontinental Exchange, Livongo Health, Nucor, Seres Therapeutics and Sunrun.
